Brief: Bioarctic To Initiate Next Cohorts In Exidavnemab Phase 2A Study After Positive Safety Review
13/06/2025 07:08
June 13 (Reuters) - BioArctic AB BIOAb.ST: TO INITIATE NEXT COHORTS IN EXIDAVNEMAB PHASE 2A STUDY AFTER POSITIVE SAFETY REVIEW Source text: ID:nWkrJ5Ctj Further company coverage: BIOAb.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))
Recent news on BioArctic AB
See all newsBrief: BioArctic And Lilly Sign Research, Collaboration Agreement
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million